{"id":93165,"date":"2022-12-15T11:43:37","date_gmt":"2022-12-15T09:43:37","guid":{"rendered":"http:\/\/realitatearutiera.ro\/?p=93165"},"modified":"2022-12-15T11:43:41","modified_gmt":"2022-12-15T09:43:41","slug":"vesti-bune-in-sanatate-tehnologie-arnm-impotriva-cancerului","status":"publish","type":"post","link":"https:\/\/realitatearutiera.ro\/?p=93165","title":{"rendered":"Ve\u0219ti bune \u00een S\u0102N\u0102TATE! Tehnologie ARNm \u00eempotriva cancerului"},"content":{"rendered":"\n<p><strong>Moderna \u0219i Merck se preg\u0103tesc s\u0103 lanseze primul studiu de faz\u0103 trei al unui vaccin \u00eempotriva cancerului cu ARN mesager. La fel ca \u0219i \u00een cazul vaccinului \u00eempotriva COVID-19, \u0219i acesta ar \u00eenv\u0103\u021ba sistemul imunitar al organismului s\u0103 \u021binteasc\u0103 celulele canceroase, potrivit Financial Times.<\/strong><\/p>\n\n\n\n<p>Moderna \u0219i Merck se preg\u0103tesc s\u0103 lanseze primul studiu de faz\u0103 trei al unui vaccin cu ARN mesager \u00eempotriva cancerului, dup\u0103 ce un studiu anterior a ar\u0103tat c\u0103 acesta a sporit \u0219ansele de supravie\u021buire ale pacien\u021bilor cu un tip agresiv de cancer de piele.<\/p>\n\n\n\n<p>Datele publicate mar\u021bi de Moderna au ar\u0103tat c\u0103 o combina\u021bie \u00eentre vaccinul experimental \u00eempotriva cancerului al companiei \u0219i medicamentul de imunoterapie Keytruda al Merck a redus cu 44% riscul de deces sau de recidiv\u0103 a melanomului la pacien\u021bii cu risc ridicat, \u00een compara\u021bie cu tratamentul care utilizeaz\u0103 doar Keytruda.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Ve\u0219ti bune \u00een S\u0102N\u0102TATE! Tehnologie ARNm \u00eempotriva cancerului: 157 de pacien\u021bi<\/h4>\n\n\n\n<p>Studiul randomizat de faz\u0103 2 a inclus 157 de pacien\u021bi care suferiser\u0103 deja o interven\u021bie chirurgical\u0103 din cauza melanomului \u0219i i-a urm\u0103rit timp de un an. Unii participan\u021bi au primit nou\u0103 doze de vaccin \u00eempotriva cancerului, \u00eempreun\u0103 cu Keytruda. Al\u021bii au primit doar Keytruda, care este tratamentul standard pentru melanomul cu stadiu ridicat.<\/p>\n\n\n\n<p>St\u00e9phane Bancel, directorul executiv al Moderna, a declarat c\u0103 rezultatele au \u00eencurajat Merck \u0219i Moderna s\u0103 se angajeze \u00een studiul de faz\u0103 3, pe care autorit\u0103\u021bile de reglementare tind s\u0103 \u00eel solicite \u00eenainte de a aproba un nou tratament.<\/p>\n\n\n\n<p>Marea majoritate a medicamentelor care reu\u0219esc \u00een studiile de faz\u0103 2 e\u0219ueaz\u0103 ulterior \u00een urm\u0103toarea etap\u0103 de studii, potrivit Financial Times.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Ve\u0219ti bune \u00een S\u0102N\u0102TATE! Tehnologie ARNm \u00eempotriva cancerului: multe tipuri de tumori<\/h4>\n\n\n\n<p>Companiile ar urma s\u0103 testeze combina\u021bia \u0219i pe alte tipuri de cancer. \u201eCredem c\u0103 aceasta ar trebui s\u0103 func\u021bioneze \u00een multe tipuri de tumori, nu numai \u00een melanom\u201d, a declarat Bancel \u00eentr-un interviu.<\/p>\n\n\n\n<p>Oamenii de \u0219tiin\u021b\u0103 au studiat de mult timp poten\u021bialul utiliz\u0103rii tehnologiei ARNm \u2013 care este cel mai bine cunoscut\u0103 pentru dezvoltarea vaccinurilor anti-Covid-19 \u2013 pentru a administra un vaccin care s\u0103 \u00eenve\u021be sistemul imunitar al organismului s\u0103 \u021binteasc\u0103 tumorile canceroase.<\/p>\n\n\n\n<p>Jeffrey Weber, cercet\u0103tor principal al studiului \u0219i director adjunct al Perlmutter Cancer Center de la NYU Langone, a declarat c\u0103 rezultatele au oferit primele dovezi randomizate c\u0103 o abordare personalizat\u0103 a vaccinului ar putea fi benefic\u0103 \u00een cazurile de melanom. Weber este consultant pl\u0103tit pentru Merck \u0219i Moderna.<\/p>\n\n\n\n<p>Julie Bauman, director al centrului de oncologie de la Universitatea George Washington, a declarat c\u0103 vaccinurile anti-cancer cu ARNm sunt special concepute pentru a viza cancerul fiec\u0103rui individ \u00een parte.<\/p>\n\n\n\n<p>\u201eOb\u021bii \u021besutul de la o tumoare, \u00eel secven\u021biezi \u0219i apoi, pe o perioad\u0103 de \u0219ase s\u0103pt\u0103m\u00e2ni, produci un vaccin care se potrive\u0219te cu primele 10-20 de muta\u021bii\u201d, a spus ea.<\/p>\n\n\n\n<p>Bauman a spus c\u0103 vaccinul stimuleaz\u0103 sistemul imunitar al unei persoane s\u0103 \u021binteasc\u0103 selectiv acele celule canceroase.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Ve\u0219ti bune \u00een S\u0102N\u0102TATE! Tehnologie ARNm \u00eempotriva cancerului: colaborare de \u0219ase ani<\/h4>\n\n\n\n<p>Studiul clinic face parte dintr-o colaborare de \u0219ase ani \u00eentre Merck \u0219i Moderna \u00een domeniul dezvolt\u0103rii de vaccinuri personalizate \u00eempotriva cancerului.<\/p>\n\n\n\n<p>Dean Li, pre\u0219edintele Merck Research Laboratories, a declarat c\u0103 rezultatele pozitive ale studiului reprezint\u0103 o etap\u0103 important\u0103 \u00een colaborarea companiei cu Moderna. \u201eA\u0219tept\u0103m cu ner\u0103bdare s\u0103 avans\u0103m acest program \u00een urm\u0103toarea faz\u0103 de dezvoltare\u201d.<\/p>\n\n\n\n<p>Sursa:romania24<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Moderna \u0219i Merck se preg\u0103tesc s\u0103 lanseze primul studiu de faz\u0103 trei al unui vaccin \u00eempotriva cancerului cu ARN mesager.<\/p>\n","protected":false},"author":1,"featured_media":93166,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"spay_email":"","footnotes":"","jetpack_publicize_message":""},"categories":[80],"tags":[],"class_list":["post-93165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sanatate"],"jetpack_featured_media_url":"https:\/\/i1.wp.com\/realitatearutiera.ro\/wp-content\/uploads\/2022\/12\/7629786-hepta-mediafax-foto-zuma-press-hepta.jpg?fit=399%2C266&ssl=1","jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p61naM-oeF","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=\/wp\/v2\/posts\/93165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=93165"}],"version-history":[{"count":1,"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=\/wp\/v2\/posts\/93165\/revisions"}],"predecessor-version":[{"id":93167,"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=\/wp\/v2\/posts\/93165\/revisions\/93167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=\/wp\/v2\/media\/93166"}],"wp:attachment":[{"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=93165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=93165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/realitatearutiera.ro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=93165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}